FTO and cancer: Inhibition of FTO with shRNAs was sufficient to suppress the expression of ZEB1 and Vimentin, promote E-cadherin expression levels (Fig. 4H and Supplementary Fig. 4E), and attenuate docetaxel resistance of cancer cells following SN-exo incubation (Fig. 4I).